Karina Pats

Elizaveta Vinogradova, Karina Pats, Ferdinand Molnár et al.

Assessing drug-target affinity is a critical step in the drug discovery and development process, but to obtain such data experimentally is both time consuming and expensive. For this reason, computational methods for predicting binding strength are being widely developed. However, these methods typically use a single-task approach for prediction, thus ignoring the additional information that can be extracted from the data and used to drive the learning process. Thereafter in this work, we present a multi-task approach for binding strength prediction. Our results suggest that these prediction can indeed benefit from a multi-task learning approach, by utilizing added information from related tasks and multi-task induced regularization.

Elizaveta Vinogradova, Abay Artykbayev, Alisher Amanatay et al.

While generative models have recently become ubiquitous in many scientific areas, less attention has been paid to their evaluation. For molecular generative models, the state-of-the-art examines their output in isolation or in relation to its input. However, their biological and functional properties, such as ligand-target interaction is not being addressed. In this study, a novel biologically-inspired benchmark for the evaluation of molecular generative models is proposed. Specifically, three diverse reference datasets are designed and a set of metrics are introduced which are directly relevant to the drug discovery process. In particular we propose a recreation metric, apply drug-target affinity prediction and molecular docking as complementary techniques for the evaluation of generative outputs. While all three metrics show consistent results across the tested generative models, a more detailed comparison of drug-target affinity binding and molecular docking scores revealed that unimodal predictiors can lead to erroneous conclusions about target binding on a molecular level and a multi-modal approach is thus preferrable. The key advantage of this framework is that it incorporates prior physico-chemical domain knowledge into the benchmarking process by focusing explicitly on ligand-target interactions and thus creating a highly efficient tool not only for evaluating molecular generative outputs in particular, but also for enriching the drug discovery process in general.